Depigmentation vs Repigmentation for Vitiligo — Which Approach Fits You?

The two strategies pull in opposite directions: bring pigment back, or take the remaining pigment away. For patients with extensive vitiligo, the decision between them is one of the most consequential medical choices in dermatology. This article walks through how to think about it.

If you have vitiligo and you’ve reached the point where you’re considering active treatment, you face a strategic choice that doesn’t get talked about enough: repigmentation therapy (try to restore the pigment you’ve lost) or depigmentation therapy (depigment the skin you still have so the body matches). Most patients spend years on the repigmentation path before the depigmentation question even comes up. Many patients are eventually offered the depigmentation option without a clear framework for evaluating it.

This article gives you that framework. It is not a recommendation for one approach over another — that decision belongs with you and your dermatologist. But the considerations below should make the decision easier to think through.

The two strategies in one paragraph each

Repigmentation therapy tries to restore melanocyte function in depigmented areas. Phototherapy, topical immunomodulators, JAK inhibitors, surgical melanocyte transplantation — all are designed to either re-activate dormant melanocytes or transplant new ones into vitiligo patches. The strategy works well in patients with limited or stable disease and remaining melanocyte reservoirs. The outcome is gradual return of pigment to depigmented patches, often partial, sometimes complete.

Depigmentation therapy does the opposite. Using monobenzone (the only FDA-approved depigmenting agent), it destroys remaining melanocytes in normally pigmented skin so the entire body matches the depigmented vitiligo patches. The strategy makes sense for patients with extensive disease where repigmentation is impractical. The outcome is uniform, permanent depigmentation.

The fork in the road is not a matter of one being “better” than the other. It’s about which strategy fits your specific situation.

When repigmentation makes sense

The repigmentation pathway is the default first-line approach for almost all vitiligo. It’s appropriate for:

• Limited disease — vitiligo affecting less than 50% of body surface area, especially less than 20-30%
• Stable disease — disease that has not been actively spreading for at least 6 months
• Recent onset — disease that started in the past 1-2 years generally responds better than long-standing disease
• Specific anatomical areas with retained melanocytes — face and torso typically have better repigmentation potential than hands and feet
• Patients who have not yet tried systematic repigmentation — many patients haven’t actually completed a full repigmentation course
• Patients who want to preserve the option of returning to natural skin tone — repigmentation is reversible (you can stop and pigment fades back); depigmentation is permanent

For these patients, depigmentation isn’t the answer. Repigmentation should be tried first, and often the full extent of what’s possible isn’t known until a systematic regimen has been attempted.

When depigmentation makes sense

The depigmentation pathway becomes a serious option when:

• Extensive disease — vitiligo affecting more than 50% of BSA, often more than 70%
• Stable disease — disease that has stopped progressing or progresses very slowly
• Repigmentation has been tried — and has produced inadequate response
• The cosmetic/social impact of patchy appearance is significant enough that uniform depigmentation is preferable
• The patient understands and accepts permanence — there’s no undo
• The patient is committed to lifelong sun protection — treated skin loses its UV defence permanently
• The patient has had time to think — this isn’t a same-day decision

Note the order of these considerations. The first is disease extent. The second is disease activity. The third is treatment history. Only after those three does the patient’s preference become the deciding factor. Skipping the first three and going directly to “I want to depigment” is a mistake — the decision needs the medical context first.

What “extensive enough for depigmentation” actually means

Different dermatologists use slightly different thresholds, but a common framing is:

• Below 50% BSA depigmented: Repigmentation is the strong recommendation
• 50-70% BSA: Depigmentation becomes a discussable option; the choice depends on disease activity, repigmentation history, and patient preference
• Above 70% BSA: Depigmentation is often the more practical option; repigmentation may still be considered but the practical limits are tight

Body Surface Area is estimated using the standard “rule of nines” or by more detailed mapping. Your dermatologist will do this estimate at your consultation. It’s typically given as a single percentage with caveats — vitiligo doesn’t always distribute uniformly, and the estimate is approximate.

The “active disease” complication

A vitiligo patient with actively progressing disease is in a different position than one with stable disease, regardless of current BSA.

• Active rapid progression: Disease may continue progressing toward universal vitiligo regardless of which treatment is chosen. Repigmentation can be undermined by ongoing immune destruction; depigmentation may proceed faster than intended because the underlying disease is contributing
• Active slow progression: A more nuanced situation; both pathways are possible but may need additional management of the underlying immune activity (oral or systemic immunomodulators)
• Stable disease: Both pathways are clear options; the choice is principally about preference and current BSA

For patients with active disease, calming the immune activity first — sometimes with oral steroids or other systemic agents — is often the right first step before deciding on depigmentation. Discuss this specifically with your dermatologist.

The reversibility question

This is the single most important practical difference:

Repigmentation is reversible. You can stop treatment, accept the result you have at that point, and resume later if you want. The pigment that returns can fade if you stop applying topical agents or stop phototherapy. The outcome is dynamic.

Depigmentation is permanent. Once monobenzone destroys melanocytes, the cells are gone. You cannot “un-depigment” treated areas. If you start the course and change your mind partway through, you’re left with a partial result — areas you treated are now depigmented; areas you haven’t yet treated remain in their pre-treatment state.

This means the timing of the decision matters more for depigmentation than for repigmentation. A premature decision to depigment is much harder to undo than a premature decision to start phototherapy.

What most patients actually choose

When patients with vitiligo above 50% BSA are presented with the full range of options, the choice distribution varies but tends toward:

• A meaningful fraction choose to continue repigmentation attempts indefinitely, even when full repigmentation is unlikely
• A meaningful fraction choose to start depigmentation when they reach the practical limits of repigmentation
• A meaningful fraction choose neither — accepting their current appearance and focusing on sun protection of depigmented areas
• A small fraction choose both at different times — repigmentation early, depigmentation later when disease has stabilised at high BSA

There is no “right” choice. The choice that fits the patient’s life is the right one. What matters is that the choice be made with awareness of the alternatives.

The cosmetic-vs-medical framing

Some patients struggle with the framing of “cosmetic” vs “medical” treatment for vitiligo. The honest position:

• Vitiligo is a medical condition (autoimmune disease) that produces a cosmetic outcome (changed appearance)
• All vitiligo treatment is therefore both medical and cosmetic
• Calling depigmentation “purely cosmetic” misses that it addresses a real medical condition with significant psychological and social effects
• Calling repigmentation “purely medical” misses that its primary benefit is also visible appearance

If you’re concerned that choosing depigmentation feels “vain,” consider that the choice you’d make if your skin were a different colour or in a different culture might also differ. The cosmetic and psychological burden of vitiligo is real and is itself a legitimate medical concern.

Special considerations

Face and hands specifically. Some patients with mostly-stable disease on the body have particularly visible vitiligo on face and hands. Even when total BSA is below the typical depigmentation threshold, severe facial or hand involvement that has failed repigmentation can be an indication for focused depigmentation in those areas alone. This is sometimes called “regional depigmentation” and is a specific decision worth discussing.

Children. Depigmentation in paediatric vitiligo is much less common and is generally reserved for specific severe cases with explicit specialist involvement. Most pediatric vitiligo is managed with repigmentation strategies and watchful waiting.

Pregnancy and breastfeeding. Depigmentation therapy is generally not started during pregnancy or breastfeeding. Active monobenzone treatment is usually paused if pregnancy occurs.

Pre-existing autoimmune conditions. Patients with other autoimmune diseases (thyroid disease, type 1 diabetes, lupus, etc.) should specifically discuss with their dermatologist whether depigmentation therapy interacts with their other conditions or treatments.

What the conversation looks like

If you’re at the stage of seriously considering depigmentation, the consultation with your dermatologist should cover at minimum:

1. Confirmation of diagnosis — vitiligo, subtype, BSA estimate
2. Treatment history — what’s been tried, with what results
3. Disease activity assessment — currently active, stable, slowly progressive
4. Realistic options — what repigmentation could still achieve, what depigmentation would look like
5. Side-effects profile of whichever path is being considered
6. Permanence — really making sure you understand it
7. Sun protection planning — particularly for depigmentation
8. Psychological readiness — open conversation about whether this is the right time
9. Logistics — prescription, sourcing, follow-up schedule

This is not a 10-minute consultation. Plan for 30-45 minutes for the decision-making conversation. If the dermatologist doesn’t give you that time, ask for a longer appointment.

For specific questions to bring, see Talking to Your Dermatologist About Depigmentation.

Frequently asked questions

Can I do both — repigment some areas and depigment others? Technically yes, but it’s rarely the right plan. Mixed regimens send conflicting signals to the immune system and tend to produce uneven results. Most dermatologists recommend committing to one strategy at a time. If you want different outcomes in different body areas, focal monobenzone (depigmenting only face and hands, for example) is more coherent than alternating between strategies.

What if I start depigmentation and partway through I want to stop? You’re left with the partial result you have. Areas you’ve treated will remain depigmented; areas you haven’t yet treated remain pre-treatment. The areas that have been treated cannot be repigmented through any reliable means. Plan accordingly.

How much does the decision depend on skin tone? Practically, the contrast between vitiligo patches and pigmented skin is more dramatic in patients with darker baseline skin, which can make the cosmetic impact of patchy disease more pronounced. Cultural and social factors vary by community. The medical principles are the same regardless of skin tone, but the lived experience may shift the decision.

Is there a way to “try” depigmentation without committing? Sort of. Some dermatologists start with a small test patch of monobenzone on a forearm or lateral neck. After 3-4 months you can see how your skin responds. The test patch itself is permanent — that area will remain depigmented — but it’s a small, hideable area and gives you real information about how you’d tolerate the full course.

What if I’m undecided? That’s a fine answer. Most patients facing this decision are undecided for months. Use the time. Read. Talk to your dermatologist multiple times. Talk to patient communities. Talk to family. The decision will become clearer or it won’t, but rushing it serves no one.

Order monobenzone with your prescription

If you and your dermatologist have decided depigmentation is the right path, EL.V. Life Sciences supplies monobenzone-based brands from a WHO-GMP plant in India against valid prescriptions. Order with prescription → or WhatsApp us.

Related: Main monobenzone landing page · Depigmentation therapy complete guide · Universal vitiligo treatment options · Talking to your dermatologist · Monobenzone before and after timeline.

Medically reviewed by Dr. [Name], MD Dermatology · Last updated 29 May 2026

You might also like

Talking to Your Dermatologist About Depigmentation — Questions to Ask

Talking to Your Dermatologist About Depigmentation — Questions to Ask Depigmentation therapy is a serious, permanent treatment. The…

Read article →

Indian Monobenzone vs US Compounded — Cost, Quality, Availability

Indian Monobenzone vs US Compounded — Cost, Quality, Availability Both are legitimate sources of monobenzone. They differ on…

Read article →

Satellite Depigmentation & “Consort Vitiligo” — Explained

Satellite Depigmentation & “Consort Vitiligo” — Explained Two documented but uncommon effects of monobenzone treatment that catch patients…

Read article →